Alzheimer's disease trials recruiting in New York

All Alzheimer's disease trials nationally

Cities in New York

Recruiting trials in New York

• A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
  NCT07033494 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female) · New York: Albany, New Windsor, Queens
• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07170150 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · New York: Rochester
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
  NCT07011745 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · New York: Brooklyn, Staten Island, Valley Stream
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
  NCT07011732 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · New York: Inwood, New Windsor, Woodmere
• A Primary Care-Based Psychosocial Intervention To Improve Cognitive & Depression Outcomes in Older Adults With MCI & Early Stage AD
  NCT05081596 · Phase: Not applicable (e.g. observational or device study) · Ages: 60 Years and older · Sex: All (male and female) · New York: White Plains
• A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
  NCT05552157 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
  NCT07717411 · Phase: Phase 3 · Ages: 55 Years to 80 Years · Sex: All (male and female) · New York: Laurelton
• A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
  NCT07169578 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · New York: Laurelton, New York, The Bronx
• A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
  NCT07633470 · Phase: Phase 4 · Ages: 50 Years and older · Sex: All (male and female) · New York: Albany
• A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
  NCT06647498 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
  NCT05511363 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · New York: Manhasset, New York, Staten Island, Stony Brook
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
  NCT06126224 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · New York: New Hyde Park, Port Jefferson Station
• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
  NCT06585787 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · New York: New Windsor, Syracuse, Woodmere
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
  NCT06976216 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female) · New York: New York, Syracuse
• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
  NCT06976203 · Phase: Phase 3 · Ages: 60 Years to 85 Years · Sex: All (male and female) · New York: Albany, Amherst, Buffalo, Lake Success
• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
  NCT06937229 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · New York: New Windsor, Staten Island, Woodmere
• ACP-204 in Adults With Alzheimer's Disease Psychosis
  NCT06159673 · Phase: Phase 2, Phase 3 · Ages: 55 Years to 95 Years · Sex: All (male and female) · New York: Amherst, Rochester, Syracuse, The Bronx
• Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
  NCT06563895 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: New York, Rosedale
• Autoimmune Features of Neurodegenerative Disorders
  NCT04239079 · Phase: Not specified · Ages: 55 Years to 90 Years · Sex: All (male and female) · New York: New York
• Aβ Dynamics in LLMD
  NCT05004987 · Phase: Phase 4 · Ages: 60 Years and older · Sex: All (male and female) · New York: New York, Orangeburg
• Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
  NCT06189963 · Phase: Phase 1, Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female) · New York: Albany
• Clinical Trial on Agitation in Alzheimer's Dementia
  NCT05543681 · Phase: Phase 2 · Ages: 60 Years and older · Sex: All (male and female) · New York: Amherst, Brooklyn, New York, Syracuse
• Daridorexant to Prevent Post-cardiotomy Delirium
  NCT07217912 · Phase: Phase 2 · Ages: 60 Years and older · Sex: All (male and female) · New York: Rochester
• Dementia Caregivers' Link to Assistance and Resources
  NCT06860035 · Phase: Not applicable (e.g. observational or device study) · Ages: No age limits stated · Sex: All (male and female) · New York: New York
• Designing Care Management for Hospice Transitions for Persons Living With Advanced Dementia
  NCT07182357 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
  NCT06584357 · Phase: Not specified · Ages: 60 Years to 90 Years · Sex: All (male and female) · New York: Albany
• Dominantly Inherited Alzheimer Network (DIAN)
  NCT00869817 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Early Age-Related Hearing Loss Investigation (EARHLI)
  NCT06174038 · Phase: Not applicable (e.g. observational or device study) · Ages: 55 Years to 75 Years · Sex: All (male and female) · New York: New York
• Enhancing Triadic Communication About Cognition for Older Adults With Alzheimer's Disease or Related Dementias Facing a Cancer Management Decision
  NCT06313853 · Phase: Not applicable (e.g. observational or device study) · Ages: 65 Years and older · Sex: All (male and female) · New York: Rochester
• Evaluating the Efficacy of the Pain Identification and Communication Toolkit
  NCT06168604 · Phase: Not applicable (e.g. observational or device study) · Ages: 21 Years and older · Sex: All (male and female) · New York: New York
• ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
  NCT03671889 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years to 85 Years · Sex: All (male and female) · New York: New York
• Genetic Studies of Early-onset Dementia
  NCT04906863 · Phase: Not specified · Ages: 35 Years and older · Sex: All (male and female) · New York: New York
• Innate Immunity Stimulation Via TLR9 in Early AD
  NCT05606341 · Phase: Phase 1 · Ages: 60 Years to 85 Years · Sex: All (male and female) · New York: New York
• Late Onset Alzheimer's Disease
  NCT05010603 · Phase: Not specified · Ages: 55 Years and older · Sex: All (male and female) · New York: New York
• Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease
  NCT04576793 · Phase: Phase 2 · Ages: 50 Years and older · Sex: All (male and female) · New York: New York
• Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
  NCT05397639 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · New York: Amherst, East Syracuse
• NYSCF Scientific Discovery Biobank
  NCT06203106 · Phase: Not specified · Ages: 30 Days and older · Sex: All (male and female) · New York: New York
• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
  NCT05980949 · Phase: Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · New York: Manhasset, New York, Stony Brook, Syracuse
• Open-label Extension Study in Participants With Early Alzheimer's Disease
  NCT07105709 · Phase: Phase 2 · Ages: 50 Years to 85 Years · Sex: All (male and female) · New York: Staten Island
• Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients
  NCT05016219 · Phase: Not applicable (e.g. observational or device study) · Ages: 55 Years and older · Sex: All (male and female) · New York: Menands, New York
• Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
  NCT07178210 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years and older · Sex: All (male and female) · New York: Buffalo
• Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease
  NCT07553338 · Phase: Phase 2 · Ages: 50 Years and older · Sex: All (male and female) · New York: New York
• Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
  NCT07284472 · Phase: Phase 2, Phase 3 · Ages: 55 Years to 90 Years · Sex: All (male and female) · New York: Brooklyn, New York
• Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
  NCT07177352 · Phase: Phase 3 · Ages: 50 Years to 90 Years · Sex: All (male and female) · New York: Laurelton, New York, Rochester, The Bronx
• Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
  NCT06847321 · Phase: Phase 2 · Ages: 55 Years to 80 Years · Sex: All (male and female) · New York: Albany, New York
• Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
  NCT06808984 · Phase: Phase 2 · Ages: 55 Years to 90 Years · Sex: All (male and female) · New York: Buffalo, Manhasset, New Windsor, Staten Island
• Tau Networks in Psychotic Alzheimer's Disease
  NCT05847192 · Phase: Not specified · Ages: 65 Years to 85 Years · Sex: All (male and female) · New York: Manhasset
• Tele-Savvy for Latino Caregivers
  NCT07290387 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · New York: Rochester
• The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study
  NCT05988385 · Phase: Not applicable (e.g. observational or device study) · Ages: 55 Years to 85 Years · Sex: All (male and female) · New York: New York
• Triage Survey for Neurology Research Eligibility
  NCT06104852 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Trial-Ready Cohort-Down Syndrome (TRC-DS)
  NCT04165109 · Phase: Not specified · Ages: 25 Years to 55 Years · Sex: All (male and female) · New York: Staten Island
• [18F]PI-2620 Phase 3 Histopathological Study
  NCT05641688 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female) · New York: East Syracuse, Syracuse